Kymera Therapeutics, Inc.

Kymera Therapeutics reported a net loss of $(61.2) million for Q2 2026, an improvement from $(76.6) million in Q2 2025. Collaboration revenue significantly increased to $65.0 million for the quarter and $99.4 million for the six months ended June 30, 2026. The company maintains a strong cash position with $1.505 billion in cash, cash equivalents, and marketable securities, expected to fund operations for at least 12 months. The filing also detailed various risks associated with drug development, regulatory approvals, and global economic conditions.

Kymera Therapeutics reported its second quarter 2026 financial results, showing a reduced net loss of $61.2 million and a significant increase in collaboration revenues to $65.0 million. The company maintains a strong financial position with $1.5 billion in cash, providing a runway into 2029. Operationally, Kymera achieved early completion of enrollment for its KT-621 BROADEN2 Phase 2b atopic dermatitis trial, accelerating data readout to year-end 2026 and planning earlier Phase 3 initiation. Additionally, the company received milestone payments totaling $65 million from its partnerships with Sanofi and Gilead Sciences.

Kymera Therapeutics, Inc. announced it will report its second quarter 2026 financial results on August 5, 2026. The clinical-stage biopharmaceutical company will host a video conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. A replay of the webcast will be available following the event.

Kymera Therapeutics, Inc. announced the retirement of Dr. Jared Gollob as Chief Medical Officer, effective July 27, 2026. Dr. Gollob will transition to an advisory role until the end of the year. Concurrently, Dr. Terence Rooney has been appointed as the new CMO, bringing extensive experience in immunology drug development from his previous role at Johnson & Johnson.

Kymera Therapeutics announced the appointment of Terence Rooney, MD, as its new Chief Medical Officer. Dr. Rooney, formerly an immunology leader at Johnson & Johnson, will lead the company's clinical development strategy for its oral immunology portfolio. He succeeds Jared Gollob, MD, who will retire after eight years but will continue as an advisor through the end of the year.

Kymera Therapeutics announced the appointment of Dr. Elizabeth Laws as Senior Vice President, KT-621 Development Program Leader. Dr. Laws, a former immunology leader at Sanofi with over two decades of biopharmaceutical experience, will oversee the global development of Kymera’s first-in-class oral STAT6 degrader, KT-621. The company also provided updates on the KT-621 program, with Phase 2b trials advancing in atopic dermatitis and asthma, expecting data by year-end 2026 and late 2027, respectively, and planning Phase 3 trials in AD to start by mid-2027.

Kymera Therapeutics announced the early completion of enrollment for its global BROADEN2 Phase 2b trial of KT-621, a STAT6 degrader for moderate to severe atopic dermatitis. This achievement, nearly six months ahead of schedule, allows the company to accelerate the expected topline data readout to year-end 2026. Kymera also plans to initiate Phase 3 trials for KT-621 in AD by mid-2027, while the BREADTH Phase 2b asthma trial continues with data anticipated in late 2027.

Kymera Therapeutics announced the appointment of Felix J. Baker, PhD, as the new Chairman of its Board of Directors. Dr. Baker, who has been the Lead Independent Director since 2024, succeeds co-founder Bruce Booth, DPhil. Dr. Booth will continue to serve as an Independent Director, ensuring continuity and leveraging his decade of leadership. The company highlighted Dr. Baker's extensive experience in scaling innovative companies and translating science into medicines as invaluable for Kymera's next phase of growth.

Kymera Therapeutics announced new data from its Phase 1 study of KT-621, an oral STAT6 degrader, in healthy Japanese adults, presented at the JDA Annual Meeting. The results showed consistent safety and pharmacokinetic/pharmacodynamic (PK/PD) profiles, including rapid and sustained STAT6 degradation, comparable to previous studies in non-Japanese adults and atopic dermatitis patients. This data supports KT-621's potential for chronic Type 2 inflammatory diseases. The company's parallel Phase 2b trials for KT-621 in atopic dermatitis and asthma are ongoing, with data expected by mid-2027 and late 2027, respectively.

Kymera Therapeutics announced the dosing of the first participant in the first-in-human Phase 1 clinical trial for KT-485 (SAR447971), an oral IRAK4 degrader. This milestone triggered a $20 million payment from its partner Sanofi. The trial, conducted by Sanofi, will evaluate KT-485 in healthy volunteers and hidradenitis suppurativa patients. Kymera is eligible for up to $975 million in additional potential milestones and has an option for a 50/50 profit split in the US.